DDInter704 DDInter1698
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020.
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Everolimus {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Everolimus {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Somapacitan
Everolimus {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Gefitinib
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Ertugliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Everolimus {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Everolimus (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Everolimus (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Everolimus (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Everolimus (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan